Identifying Subgroups With High Cardiovascular Risk in Breast Cancer Survivors

NCT ID: NCT02485626

Last Updated: 2016-10-31

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 628 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2015-04-30
• Study Completion Date: 2019-12-31

Brief Summary

The purpose of this study is to evaluate the prevalence of (sub)clinical cardiovascular disease, cardiovascular risk factors and metabolic abnormalities among long-term breast cancer survivors treated with or without anthracyclines in order to identify patients at increased risk of developing cardiovascular disease.

Detailed Description

Rationale: Breast cancer (BC) incidence is increasing, while mortality from BC is decreasing. Since the life expectancy of BC patients is improving, the evaluation of treatment-associated cardiovascular disease (CVD) in BC survivors is becoming increasingly important. An excess risk of CVD, mainly due to coronary heart disease (CHD), has been observed after radiotherapy (RT) as administered in the 1960s-1980s. Anthracycline-containing CT and trastuzumab are known to induce cardiotoxicity, especially congestive heart failure (CHF). However, the long-term risks of CVD after anthracycline-containing CT, trastuzumab, hormonal therapy (HT) and contemporary RT techniques have hardly been examined. Furthermore, the potential interaction of these treatment modalities has not been well addressed, and there is limited knowledge about the contribution of classic cardiovascular risk factors and the metabolic syndrome to risk and severity of treatment-associated CVD in BC survivors.

Objectives: • to evaluate the prevalence of (sub)clinical CVD, cardiovascular risk factors and metabolic abnormalities among BC survivors treated with and without anthracyclines in two groups at (a) 5 - 7 years and (b) 10 - 12 years after diagnosis;

• to prospectively evaluate changes in prevalence of (sub)clinical CVD, cardiovascular risk factors and metabolic abnormalities after two years in the same patients.

Secondary objectives are to evaluate the predictive role of newly developed markers for CVD and to evaluate the effects of other BC treatment modalities, psychosocial outcomes, endocrine function and menopausal status on the risk of developing (sub)clinical CVD.

Study design: multicenter (AVL and UMCG) cross-sectional cohort study with prospective monitoring of the same cohort.

Study population: female BC survivors treated with and without anthracyclines 5 - 7 and 10 - 12 years ago at the AVL or UMCG, aged 40-50 years at time of therapy.

Main study parameter: the difference in (sub)clinical cardiovascular damage between patients treated with and without anthracyclines, as measured by left ventricular function parameters.

Conditions

Breast Neoplasms; Cardiovascular Diseases

Keywords

Anthracyclines

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Anthracycline treated BC patients

AVL or UMCG patients between the age of 40 - 50 at the time of BC diagnosis and treatment, treated with anthracyclines respectively 5-7 years ago and 10-12 years ago.

2D tissue doppler echocardiography

Intervention Type: PROCEDURE

Anthracycline naive BC patients

AVL or UMCG patients between the age of 40 - 50 at the time of BC diagnosis and treatment, treated without anthracyclines respectively 5-7 years ago and 10-12 years ago.

2D tissue doppler echocardiography

Intervention Type: PROCEDURE

Interventions

2D tissue doppler echocardiography

Intervention Type: PROCEDURE

Other Intervention Names

laboratory biomarker analyses; vascular ultrasound; strain and strain rate parameters; genetic analysis; questionnaire administration; quality of life assessment; anxiety and depression assessment

Eligibility Criteria

Inclusion Criteria

• early invasive BC (TNM stage I - III);
• diagnosed and/or treated in the AVL or UMCG;
• treated 5 - 7 years or 10 - 12 years ago;
• aged 40-50 years at time of therapy;
• signed written informed consent.

Exclusion Criteria

• history of RT or CT unrelated to BC;
• current treatment for BC recurrence or second malignancy (including contralateral BC) with the exception of non-melanoma skin cancer or curatively treated carcinoma in situ of the cervix;
• history of cardiac disease (CHF, acute coronary syndrome, coronary revascularization procedure, symptomatic valvular dysfunction, cardiomyopathy or congenital heart defect) before diagnosis and treatment for BC;
• mental disability or psychological condition potentially hampering compliance with the study protocol;
• insufficient understanding of the Dutch language.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

University Medical Center Groningen

OTHER

Sponsor Role: collaborator

The Netherlands Cancer Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Flora E. van Leeuwen, Prof. dr.

Role: PRINCIPAL_INVESTIGATOR

The Netherlands Cancer Institute

Locations

NKI-AVL

Amsterdam, , Netherlands

Site Status: RECRUITING

UMCG

Groningen, , Netherlands

Site Status: RECRUITING

Countries

Netherlands

Central Contacts

Flora E. van Leeuwen, Prof. dr.

Role: CONTACT

Email: f.v.leeuwen@nki.nl

Jourik A. Gietema, Prof. dr.

Role: CONTACT

Email: j.a.gietema@umcg.nl

References

van Ommen-Nijhof A, Jacobse JN, Steggink LC, Lefrandt JD, Gietema JA, van Leeuwen FE, Schaapveld M, Sonke GS. Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors. Breast Cancer Res Treat. 2022 Dec;196(3):591-602. doi: 10.1007/s10549-022-06714-0. Epub 2022 Oct 1.

Reference Type: DERIVED

PMID: 36181605 (View on PubMed)

Other Identifiers

NL49405.031.14

Identifier Type: -

Identifier Source: org_study_id